8.66
+0.44(+5.35%)
Currency In USD
Address
Building 14
Stafford, TX 77477
United States of America
Phone
832 819 3232
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
September 25, 2020
| Name | Title | Pay | Year Born |
| Mr. Snehal S. Patel | Chief Executive Officer, Chief Financial Officer & Director | 918,844 | 1964 |
| Mr. Eric Rothe | Founder & Independent Director | 0 | 1975 |
| Dr. Christine T. Fischette Ph.D. | Vice President of Business Development | 0 | 1951 |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs | 0 | 1966 |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director | 0 | 1951 |
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.